May 28, 2008-The European Medicines Agency (EMEA) has been formally notified by sanofi-aventis of its decision to withdraw the application for a centralised marketing authorisation for the medicine Aquilda (satavaptan) 5 and 25 mg film-coated tablets. Aquilda was intended to be used for the treatment of euvolaemic and hypervolaemic dilutional hyponatraemia, a metabolic condition in which the body’s blood sodium level falls below normal.
The application for marketing authorisation for Aquilda was submitted to the EMEA on 30 May 2007.
The details can be read here.
No comments:
Post a Comment